NIB biotec

In just a few weeks, the European Association of Urology EAU Congress 2025 will take place in Madrid from March 21-24. This prestigious event is a key platform for presenting groundbreaking clinical studies in the field of urology. NIB biotec is proud to announce that data from two significant studies that promise to advance the diagnosis and management of prostate cancer will be presented: ✅ A0700: "Improving clinical decision-making in PIRADS 3 lesions: superior diagnostic value of PSA and urinary zinc over PSA density". - In the "Urinary and semen biomarkers" session, it will be shown how urinary PSA and zinc tests offer superior diagnostic capabilities compared to PSA density (PSAD) in identifying prostate cancer in patients with PIRADS 3 lesions. This approach could significantly reduce unnecessary biopsies, with only a minimal number of potentially indolent tumors being missed. If validated, this tool could become a valuable asset in clinical practice. ✅ A0704: "Urinary PSA and zinc: Novel biomarkers for differentiating progressive and indolent prostate cancer". - In the "Prognostic biomarkers" session, it will be explored how measuring urinary biomarkers such as PSA and zinc can enhance the identification of potentially indolent prostate tumors. This approach may improve the selection of patients who could benefit from active surveillance, thereby reducing unnecessary treatments and focusing on personalized patient care. These studies highlight the importance of developing diagnostic and prognostic tests to improve the management of prostate cancer. We look forward to sharing our findings and contributing to the advancement of urological care. Stay tuned for more updates from EAU25! #EAU25 #Urology #ProstateCancer #Biomarkers #NIBBiotec #ClinicalResearch #urology #EAU

In just a few weeks, the European Association of Urology EAU Congress 2025 will take place in Madrid from March 21-24. This prestigious event is a key platform for presenting groundbreaking clinical studies in the field of urology. NIB biotec is proud to announce that data from two significant studies that promise to advance the diagnosis and management of prostate cancer will be presented: ✅ A0700: "Improving clinical decision-making in PIRADS 3 lesions: superior diagnostic value of PSA and urinary zinc over PSA density". - In the "Urinary and semen biomarkers" session, it will be shown how urinary PSA and zinc tests offer superior diagnostic capabilities compared to PSA density (PSAD) in identifying prostate cancer in patients with PIRADS 3 lesions. This approach could significantly reduce unnecessary biopsies, with only a minimal number of potentially indolent tumors being missed. If validated, this tool could become a valuable asset in clinical practice. ✅ A0704: "Urinary PSA and zinc: Novel biomarkers for differentiating progressive and indolent prostate cancer". - In the "Prognostic biomarkers" session, it will be explored how measuring urinary biomarkers such as PSA and zinc can enhance the identification of potentially indolent prostate tumors. This approach may improve the selection of patients who could benefit from active surveillance, thereby reducing unnecessary treatments and focusing on personalized patient care. These studies highlight the importance of developing diagnostic and prognostic tests to improve the management of prostate cancer. We look forward to sharing our findings and contributing to the advancement of urological care. Stay tuned for more updates from EAU25! #EAU25 #Urology #ProstateCancer #Biomarkers #NIBBiotec #ClinicalResearch #urology #EAU

We are thrilled to announce that NIB biotec has been selected to participate in the prestigious EIT Health InnoStars SPICE program with other innovative europen organisations: BestHealth4U CoNurse Check Point Care iLoF Neofunction Robota This incredible opportunity will provide us with: 💰 Financial Support to engage top professionals from the EIT Health network. 🧑🏫 Tailored Mentoring to guide our unique project needs. 📈 Development and Commercialisation Services to ensure market readiness. 🌐 Access to Extensive Expertise and Network within the InnoStars community. We are eager to leverage this support to accelerate the development and commercialisation of our innovative healthcare solutions. Stay tuned for more updates as we embark on this exciting journey to improve healthcare outcomes! #InnoStarsSPICE #HealthInnovation #StartupSupport #NIBbiotec #EITHealth

We are thrilled to announce that NIB biotec has been selected to participate in the prestigious EIT Health InnoStars SPICE program with other innovative europen organisations: BestHealth4U CoNurse Check Point Care iLoF Neofunction Robota This incredible opportunity will provide us with: 💰 Financial Support to engage top professionals from the EIT Health network. 🧑🏫 Tailored Mentoring to guide our unique project needs. 📈 Development and Commercialisation Services to ensure market readiness. 🌐 Access to Extensive Expertise and Network within the InnoStars community. We are eager to leverage this support to accelerate the development and commercialisation of our innovative healthcare solutions. Stay tuned for more updates as we embark on this exciting journey to improve healthcare outcomes! #InnoStarsSPICE #HealthInnovation #StartupSupport #NIBbiotec #EITHealth

The EIT Community RIS Hub Italy launch event is taking place at Tecnopolo Manifattura in Bologna. This incredible event is highlighting the importance of building a robust ecosystem across various sectors, fostering collaboration among businesses, institutions, and researchers. Marta Molinero, EIT Community Officer for EIT Community Hub Italy & EIT Manufacturing South, kicked off the event by showcasing the diverse sectors EIT - European Institute of Innovation and Technology is involved in, ranging from food and manufacturing to digital, health, culture, climate, and more. In a rapidly evolving world, creating synergies that can accelerate technological development and support economic growth is crucial. The EIT Community Hub Italy is a significant step towards building a more innovative and sustainable future for our country. NIB biotec has already benefited from several EIT Health programs, including Wild Card and Fast Track, as well as EIT Health InnoStars initiatives like the InnoStars Award and InnoStars Connect. These programs have been fundamental to our growth and success. Thanks Chiara Maiorino for mentonioning the results we obtained together. We are proud to contribute to this growth and to be an active part of the innovation landscape in Italy. #EITCommunityHub #Innovation #EIT #EIThealth #NIBBiotec

Oggi nasce EIT Community RIS Hub Italy. Obiettivo: supportare l’ecosistema d’innovazione italiano attraverso gli strumenti di EIT - European Institute of Innovation and Technology e delle sue 9 KICs (Knowledge Innovation Community). Buona la prima (come si suol dire)! Complimenti agli enti che hanno organizzato, specialmente a Marta Molinero. E grazie ai membri italiani di EIT Health InnoStars, sempre presenti e aperti a nuove collaborazioni! EIT Health EIT Manufacturing EIT Food EIT RawMaterials EIT Digital EIT InnoEnergy EIT Climate-KIC RIS EIT Culture & Creativity EIT Urban Mobility

Cari amici e sostenitori, Oggi desidero porre l'attenzione sull'importanza della prevenzione e dello screening nel contrasto al tumore della prostata. Recenti studi hanno evidenziato che pratiche di screening variano significativamente in Europa, influenzando l'incidenza e la mortalità della malattia. In particolare, una ricerca pubblicata sul British Medical Journal ha mostrato un aumento generale dell'incidenza del cancro della prostata dal 1980 al 2017, con variazioni notevoli tra i paesi europei. Questa tendenza è strettamente correlata alle diverse pratiche di screening con il test del PSA. Nonostante l'aumento delle diagnosi, la mortalità è leggermente diminuita, probabilmente grazie ai progressi nei trattamenti. Tuttavia, il test del PSA indiscriminato, può portare a sovradiagnosi e sovratrattamenti, sollevando interrogativi sulla sua appropriatezza nella popolazione generale. Le nuove linee guida suggeriscono l'uso della risonanza magnetica prima delle biopsie in caso di livelli anomali di PSA, al fine di evitare diagnosi inutili senza trascurare i tumori aggressivi. In Europa Uomo, promuoviamo una cultura della prevenzione consapevole, incoraggiando gli uomini a informarsi sulle opzioni di screening disponibili e a discutere con i propri medici i benefici e i potenziali rischi associati. Una diagnosi precoce, ottenuta attraverso pratiche di screening appropriate, può fare la differenza nel trattamento e nella prognosi del tumore alla prostata. Un caro saluto, Claudio Talmelli Presidente di Europa Uomo Italia #Prevenzione #Screening #TumoreProstata #EuropaUomo #SaluteMaschile #DiagnosiPrecoce

It was great to see a packed house earlier this week to listen to our EIT Health panel at the DxPx Conference entitled 💸"The Importance of Public Funding in a Challenging Environment" 💸 🎆 Some valuable takeaways from our discussion in case you missed it: 👍 Public funding can bring more than #capital, it can also be a great way to show early #traction to #investors! ✅ Consortium projects bring certain challenges, but can be a great support for companies to establish a network of partners across #Europe 🥶 The investor climate is chilly right now...with a 30% drop in the number of European venture capital funds this year, so it is important to keep scanning for relevant grant opportunities, even as your company scales! 😵💫 Make sure to read the fine print of call documents! Eligibility criteria are complex and applications can be very time consuming, make sure you are a good fit and take the time to properly apply so you do not get disqualified due to mistakes or misunderstandings Thanks again to... 👉 Ralph Steidl of Portabiles HealthCare Technologies in Germany 👣 👉 Peeter Padrik of Antegenes in Estonia 🧬 👉Séverin Benizri of Apneal in France 💤 👉Sergio Occhipinti of NIB biotec in Italy 🧪

Sala conferenze gremita per l'evento 𝗩𝗲𝗻𝘁𝘂𝗿𝗲 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗳𝗼𝗿 𝗟𝗶𝗳𝗲-𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗕𝗶𝗼𝗧𝗲𝗰𝗵: 𝗕𝗿𝗶𝗱𝗴𝗶𝗻𝗴 𝘁𝗵𝗲 𝗴𝗮𝗽 𝗶𝗻 𝘀𝗲𝗲𝗱 𝗮𝗻𝗱 𝗲𝗮𝗿𝗹𝘆 𝘀𝘁𝗮𝗴𝗲 𝗶𝗻𝘃𝗲𝘀𝘁𝗶𝗻𝗴, tenuto in Fondazione UNIMI lo scorso 22 gennaio in collaborazione con Capital Cell. Si inaugura così una serie di appuntamenti in programma nei prossimi mesi, pensata per mettere sotto la lente d'ingrandimento la rivoluzione in atto nell'ecosistema tecnologico medicale a partire dalle testimonianze di realtà innovative impegnate a sviluppare soluzioni all'avanguardia. MgShell, Rilemo (ex. Previeni) e le nostre incubate NIB biotec e TT3A le prime a presentare la loro storia. Università degli Studi di Milano Antonio Servadio 📌 Sergio Occhipinti Paolo Gazzaniga Alessandro Pizzo Marco Ferroni Valentina Lidoni Riccardo Aimerito #venturecapital #innovation #biotech

DxPx Conference is taking place in Munich! This prestigious event is a key gathering for innovation in diagnostics and life sciences, bringing together startups, investors, and industry leaders. At NIB biotec, we are pioneering a point-of-care test for prostate cancer, utilizing proprietary biomarkers to deliver rapid and accurate results. Our goal is to reduce unnecessary biopsies, lower healthcare costs, and enhance the quality of life for men globally. With the support of EIT Health funding, we are currently in the industrialization and clinical validation phase. We are now seeking additional resources to commercialize our test in Europe and initiate the validation process in the USA. If you are an investor or a company in the diagnostics sector interested in collaboration, we would love to connect with you at DxPx! Let's explore how we can work together to bring this innovative solution to market and make a significant impact on prostate cancer diagnosis and treatment. #DxPx2025 #Diagnostics #Innovation #Healthcare #Startups #Investors #NIBBiotec #Fundraising https://lnkd.in/dvhxDxZs